文献速递核素与放射性配体治疗肿瘤 PET/CT放射性药物与辐射防护

177Lu-PSMA-617放射性配体治疗在单肾功能转移性去势抵抗性前列腺癌患者中的应用

177Lu-PSMA-617 Radioligand Therapy in Metastatic Castration-Resistant Prostate Cancer Patients with a Single Functioning Kidney.
PubMed 文献 · J Nucl Med · 2019-03-08

中位给药活度22.1 GBq,每周期肾脏吸收剂量5.3±2.1 Gy(0.81±0.32 Gy/GBq)。未观察到CTCAE 3级或4级肾毒性,肾小管提取率无显著变化,中位无进展生存期8.1个月,中位总生存期未达到,中位随访19.3个月。结论认为该治疗在单肾功能患者中可行、有效且耐受良好。

要点

  • 单肾功能患者接受177Lu-PSMA-617治疗未出现CTCAE 3级或4级肾毒性。
  • 治疗后肾小管提取率及其与正常下限比值无显著变化(P>0.05)。
  • 中位无进展生存期8.1个月,中位总生存期未达到,中位随访19.3个月。

核心结论

  • 在单肾功能患者中,177Lu-PSMA-617放射性配体治疗可行、似乎有效且耐受良好,平均随访近2年(最长45.3个月)未出现急性或亚急性肾毒性迹象。

研究设计与样本

  • 前瞻性结构化数据库记录肾功能参数(血清肌酐、血尿素氮、电解质),每周期治疗前及随访中分析,并用99mTc-巯基乙酰三甘氨酸肾显像测量肾小管提取率(TER)量化肾功能。
  • 治疗相关不良事件按CTCAE 5.0版分级,Kaplan-Meier分析无进展生存期和总生存期。

主要发现

  • 中位给药活度22.1 GBq(范围15.4-33.8 GBq),每周期计算肾脏吸收剂量5.3±2.1 Gy(0.81±0.32 Gy/GBq)。
  • 基线时43.7%患者已有肾功能损害,包括CTCAE 1级25.0%和2级18.8%。
  • 第一个PRLT周期后CTCAE 1级和2级肾损害分别为37.5%和6.3%,第二个周期后分别为31.3%和12.5%。
  • 治疗期间及治疗后未观察到CTCAE 3级或4级肾毒性。
  • 末次治疗后TER或TER与正常下限TER比值均无显著变化(P>0.05)。

关键数值与推荐

  • 肾损害按CTCAE 5.0版分级:基线1级25.0%、2级18.8%;第一周期后1级37.5%、2级6.3%;第二周期后1级31.3%、2级12.5%。
  • 每周期肾脏吸收剂量5.3±2.1 Gy(0.81±0.32 Gy/GBq),中位给药活度22.1 GBq(范围15.4-33.8 GBq)。
  • 中位无进展生存期8.1个月(EORTC和RECIST标准),中位总生存期未达到,中位随访19.3个月(范围5.8-45.3个月)。

临床怎么用

  • 对单肾功能mCRPC患者,177Lu-PSMA-617 PRLT可作为可行治疗选择,治疗期间未出现严重肾毒性。
  • 治疗前后应监测肾功能参数(血清肌酐、血尿素氮、电解质)及肾小管提取率,但本研究显示TER无显著变化。
  • 需注意基线时近半数患者已有肾功能损害,治疗中应个体化评估风险获益。

局限性

  • 作者指出需对该特殊患者群体进行进一步长期随访。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The aim of this study was to assess the safety, tolerability, and effects on renal function as well as therapeutic efficacy of prostate-specific membrane antigen (PSMA)-targeted radioligand therapy (PRLT) using 177Lu-labeled PSMA-617 in patients with metastatic castration-resistant prostate cancer and a single functioning kidney before PRLT. Methods: Sixteen patients (aged 53-78 y; mean age, 64.7 ± 6.5 y) with a single functioning kidney received PRLT with 177Lu-PSMA-617 between March 2015 and October 2018. All parameters of renal function (serum creatinine, blood urea nitrogen, and electrolytes) were prospectively documented in a structured database and analyzed before each PRLT cycle and in follow-up. Renal function was further quantified by measuring tubular extraction rate (TER) using 99mTc-mercaptoacetyltriglycine renal scintigraphy. Treatment-related adverse events were graded according to the Common Terminology Criteria for Adverse Events (CTCAE), version 5.0. Kaplan-Meier analysis was performed to obtain the progression-free survival and overall survival. Results: The median administered activity was 22.1 GBq (range, 15.4-33.8 GBq). The calculated absorbed radiation dose to the kidney per cycle was 5.3 ± 2.1 Gy (0.81 ± 0.32 Gy/GBq). Renal function was already impaired at baseline in 43.7% of patients, including CTCAE grade 1 renal impairment in 25.0% and CTCAE grade 2 in 18.8%. Grade 1 and 2 renal impairment, respectively, were present in 37.5% and 6.3% of the patients after the first PRLT cycle and in 31.3% and 12.5% after the second cycle. No CTCAE grade 3 or 4 nephrotoxicity was observed during or after treatment. There was no significant change in either TER or the ratio of TER to lower-limit TER after the last cycle of treatment (P > 0.05). The median PFS was 8.1 mo based on both the criteria of the European Organization for Research and Treatment of Cancer and RECIST. The median overall survival has yet to be reached with a median follow-up time of 19.3 mo (range, 5.8-45.3 mo). Conclusion: In patients with a single functioning kidney, 177Lu-PSMA-617 PRLT is feasible, seems to be effective, and is well tolerated, without any signs of acute or subacute nephrotoxicity during a mean follow-up of nearly 2 y (and up to 45.3 mo). Further long-term follow-up of this special patient group is warranted.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Zhang J, Kulkarni HR, Singh A, et al. 177Lu-PSMA-617 Radioligand Therapy in Metastatic Castration-Resistant Prostate Cancer Patients with a Single Functioning Kidney. J Nucl Med. 2019. PMID: 30850499. doi:10.2967/jnumed.118.223149

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。